Macrolides

A group of often glycosylated macrocyclic compounds formed by chain extension of multiple PROPIONATES cyclized into a large (typically 12, 14, or 16)-membered lactone. Macrolides belong to the POLYKETIDES class of natural products, and many members exhibit ANTIBIOTIC properties.

Also Known As:

Networked: 4391 relevant articles (442 outcomes, 565 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kohno, Shigeru: 25 articles (09/2019 - 05/2002)
2.	Yanagihara, Katsunori: 23 articles (10/2021 - 05/2002)
3.	Mukae, Hiroshi: 22 articles (12/2022 - 05/2002)
4.	Daley, Charles L: 17 articles (01/2022 - 09/2012)
5.	Sunazuka, Toshiaki: 17 articles (01/2020 - 05/2004)
6.	Koh, Won-Jung: 16 articles (09/2019 - 01/2008)
7.	Kudoh, Shoji: 16 articles (01/2019 - 01/2002)
8.	Izumikawa, Koichi: 14 articles (01/2022 - 04/2005)
9.	Miyashita, Naoyuki: 14 articles (01/2022 - 01/2007)
10.	Shin, Sung Jae: 14 articles (01/2020 - 07/2012)

Related Diseases

1.	Infections 01/01/2022 - "However, in the context of a high prevalence of the parC S83I mutation (23%) in macrolide-resistant infections, doxycycline + moxifloxacin cured only 85%. " 01/01/2022 - "Combination doxycycline + azithromycin achieved high cure for macrolide-susceptible infections. " 05/01/2011 - "The main aim of their use is to treat infection, but anti-inflammatory properties of macrolides are also beneficial in selected diseases. " 11/01/1993 - "Newer products with improved features have recently been discovered and developed, maintaining or significantly expanding the role of macrolides in the management of infection. " 01/01/2021 - "Resistance to macrolides, the first-line treatment for M. pneumoniae infection, is a major global public health concern. "
2.	Pneumonia (Pneumonitis) 04/01/2014 - "CRP was the only significant factor in predicting the efficacy of macrolides in patients with MRMP pneumonia. " 01/01/2010 - "Evidence derives from several retrospective studies have shown a significant reduction of mortality from community-acquired pneumonia upon treatment with a macrolide. " 04/01/2014 - "Serum CRP could be a useful marker for predicting the efficacy of macrolides and helping clinicians make better clinical decisions in children with MRMP pneumonia." 10/01/2013 - "Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy." 01/01/2019 - "The use of macrolides against pneumonia has been reported to improve survival; however, little is known about their efficacy against methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. "
3.	Asthma (Bronchial Asthma) 01/01/2010 - "In some of the studies on eradication with macrolides promising results have been gained in terms of asthma control, but in most of the cases improvement was only temporary." 03/01/2020 - "Are macrolides beneficial in treating childhood asthma?" 08/01/2013 - "Macrolide administration for asthma for three or more weeks was not associated with improvement in FEV1, but produced significant improvements in peak expiratory flow, symptoms, quality of life, and airway hyper-reactivity. " 10/19/2005 - "To determine whether macrolides are effective in the management of patients with chronic asthma. " 07/20/2005 - "To determine whether macrolides are effective in the management of patients with chronic asthma. "
4.	Diffuse panbronchiolitis 01/01/2007 - "Chronic, low-dose macrolides have dramatically improved survival in patients with diffuse panbronchiolitis (DPB). " 04/01/2004 - "Macrolides have been shown to be effective in treating diffuse panbronchiolitis (DPB), although the precise modes of action remain unclear. " 02/01/2004 - "This led to studies of the macrolides in other chronic airway diseases, such as diffuse panbronchiolitis (DPB), a disease occurring primarily in East Asia. " 01/01/2016 - "Benefits of macrolide usage and bacteriological profile in patients with diffuse panbronchiolitis." 01/25/2015 - "Macrolides for diffuse panbronchiolitis."
5.	Inflammation (Inflammations) 03/01/2004 - "The main question regarding the future prospects of this class of drugs is whether some macrolides are beneficial in such settings because they modulate host inflammatory responses (and cellular targets) or rather because they eliminate a latent, unidentified pathogen which triggers chronic inflammation. " 01/01/2012 - "These secondary anti-inflammatory activities of macrolides appear to be particularly effective in attenuating neutrophil-mediated inflammation. " 01/01/2012 - "These results indicate that the 15-member macrolide, AZM, exerts direct inhibitory effects on mucus secretion from airway epithelial cells and that it may be useful for the treatment of mucus hypersecretion caused by allergic inflammation and LPS stimulation." 03/01/2012 - "Although the methods and experimental model systems used in these studies are very heterogeneous, macrolides in general tempered inflammation caused by viable and non-viable bacteria or their products. " 01/01/2001 - "In animal studies macrolides have increased mucociliary transport, reduced goblet cell secretion and accelerated apoptosis of neutrophils, all factors that may reduce the symptoms of chronic inflammation. "

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	Azithromycin (Zithromax)
3.	Clarithromycin (Biaxin)
4.	Macrolides
5.	Erythromycin (Erycette)
6.	Fluoroquinolones
7.	Penicillins (Penicillin)
8.	Roxithromycin
9.	beta-Lactams
10.	Tetracyclines

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Highly Active Antiretroviral Therapy (HAART)
4.	Oral Administration
5.	Transplantation